- Home
- ICU vs CHRO Comparison
ICU vs CHRO Comparison
Compare ICU & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- CHRO
- Stock Information
- Founded
- ICU 2018
- CHRO 2002
- Country
- ICU United States
- CHRO United States
- Employees
- ICU N/A
- CHRO N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- CHRO
- Sector
- ICU Health Care
- CHRO
- Exchange
- ICU Nasdaq
- CHRO Nasdaq
- Market Cap
- ICU 10.4M
- CHRO 8.4M
- IPO Year
- ICU N/A
- CHRO 2024
- Fundamental
- Price
- ICU $1.18
- CHRO $0.97
- Analyst Decision
- ICU
- CHRO Strong Buy
- Analyst Count
- ICU 0
- CHRO 1
- Target Price
- ICU N/A
- CHRO N/A
- AVG Volume (30 Days)
- ICU 144.0K
- CHRO 84.7K
- Earning Date
- ICU 05-14-2025
- CHRO 05-13-2025
- Dividend Yield
- ICU N/A
- CHRO N/A
- EPS Growth
- ICU N/A
- CHRO N/A
- EPS
- ICU N/A
- CHRO N/A
- Revenue
- ICU $428,000.00
- CHRO N/A
- Revenue This Year
- ICU $648.15
- CHRO N/A
- Revenue Next Year
- ICU $100.00
- CHRO N/A
- P/E Ratio
- ICU N/A
- CHRO N/A
- Revenue Growth
- ICU N/A
- CHRO N/A
- 52 Week Low
- ICU $1.11
- CHRO $0.45
- 52 Week High
- ICU $13.85
- CHRO $3.80
- Technical
- Relative Strength Index (RSI)
- ICU 35.77
- CHRO 34.89
- Support Level
- ICU $1.13
- CHRO $0.91
- Resistance Level
- ICU $1.34
- CHRO $1.06
- Average True Range (ATR)
- ICU 0.07
- CHRO 0.09
- MACD
- ICU 0.00
- CHRO 0.00
- Stochastic Oscillator
- ICU 23.81
- CHRO 6.24
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.